And there you have it;
”This combination study will run in parallel with the phase 2 DEP® docetaxel trial program, which is currently recruiting at sites in the UK“.
So the never-ending Phase 2 trial which was supposed to be finished in the first half of CY2020 is actually still recruiting. It’s not going to end anytime soon. Maybe the Quarterly Report will shed some more light on the trial and revised timeframe.
Ann: DEP docetaxel and gemcitabine combination trial commences, page-3
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |